The government has announced that a salivary test, still at the experimental stage, aimed at detecting endometriosis will be taken care of for certain patients from Tuesday, February 11, 2025.
- As of this Tuesday, February 11, the salivary tests to detect endometriosis, designed by the Lyonnaise Ziwig biotech, will be reimbursed.
- About 25,000 women over the age of 18 for which endometriosis is suspected will be able to benefit from these devices still at the experimental stage.
- “As soon as we have the results concerning these patients, the high authority of health will give a final opinion which will make it possible to highlight the merits of the test and, behind, a care for all the women of our country,” said declared Catherine Vautrin.
“800 euros”. It is the cost of saliva tests detecting endometriosis by saliva thanks to the analysis and sequencing of the RNA (“endotest”), which were designed by the Lyonnaise Ziwig biotech. On France 2Catherine Vautrin, announced, after having already spoken of it upon his arrival at the government in early 2024, that this system will be reimbursed by health insurance from Tuesday, February 11.
Endometriosis: around 25,000 women will have access to saliva diagnostic tests
In detail, 25,000 patients over the age of 18, for whom endometriosis is suspected, will be able to benefit from it in the coming months. An estimate that remains “theoretical” according to the minister’s office. The first 2,500 patients will be included in a clinical study, the results of which (decrease in the number of diagnostic surgeries, impact on overall management) will condition any generalization of the reimbursement.
Currently, the salivary tests supported are still at the experimental stage. “As soon as we have the results concerning these patients, the high authority of health will give a final opinion which will make it possible to highlight the merits of the test and, behind, a care for all the women of our country”, said Catherine Vautrin.
The deployment of salivary tests, which will be available in 80 French hospitals, is part of the innovation package. The latter “Consists of early and derogatory management of medical devices and innovative acts, conditioned on carrying out clinical and possibly medico-economic studies to provide missing data.”
Endometriosis is slow to be diagnosed with an average period of 7 years
Currently, endometriosis would concern one in 10 menstruated people in France. This disease, whose diagnostic wandering is seven years, is characterized by the development of the internal uterine mucosa (the endometrium) outside the uterus, sometimes colonizing other organs. Fragments of endometrium are then deposited on the ovaries, the bladder, the rectum, the peritoneum and can cause pelvic, abdominal and/or lumbar cramps. This pathology is also manifested by pain during sex, infertility or even digestive or urinary problems.
